vitamin d decreases LDL/increases HDL

there are a plethora of articles on the potential benefits of vitamin d. as noted in many prior blogs, vitamin d receptors exist throughout the body. some vitamin d benefits are well-documented (bone, muscle, decrease in falls in elderly), some have small studies to support (improved response of TB to medications in those with adequate vitamin d levels, improved glucose tolerance), and many are epidemiologic studies (cancer -- including prostate, breast, ovary; all-cause mortality; immunologic function and decrease in immunologic diseases -- eg multiple sclerosis; heart disease,...) -- for example, see vit d. Endocrine Guidelines 2011 in dropbox, or doi: 10.1210/jc.2011-0385 for the endocrine society recommendations. the present article (see vit d and lipids menopause 2014 in dropbox, or DOI: 10.1097/gme.0000000000000188) supports a role in cholesterol profiles, from the Women's Health Initiative calcium/vitamin D randomized trial. in brief, 

--600 postmenopausal women (300 white, 200 African-American, 100 Latino) selected randomly from the Women's Health Initiative CaD trial, randomized to elemental Ca 1,000 mg plus vit d 400IU/d vs placebo. 576 women with data to analyze: lipids assessed before and after the randomization. after 2 years:
    --38% increase in 25OHD3 levels in those supplemented -- 24.3 vs 18.2 ng/ml
    --those on supplementation had 4.46 mg/dl decrease in LDL, nonsignif increase in HDL and nonsignif decrease in triglycerides (TG)
    --those wtih higher 25OHD3 levels had higher HDL levels and lower LDL and TG. their figure discloses a linear relationship between increasing 25OHD3 levels on the range of 5-100 ng/ml and decreasing LDL as well as increasing HDL (dose-response curve), with a more complex relation with TG (decline begins around 15 ng/ml with linear decrease from that point to 100 ng/ml).

so, from this study the combo of ca/vit d helps lipids (though this is surrogate marker ... really need to look at clinical events). unclear if vit d or calcium or combo is most beneficial. there are some data, for example, finding that calcium citrate by itself may have more beneficial lipid effect than calcium carbonate (used in this trial). one advantage of this study is that they looked at actual 25OHD3 levels achieved and lipid endpoints, instead of ecologic data based on general vitamin D supplementation and clinical results. and, in general, there was a clear, dose-response between the achieved vit D level and lipid markers. so, this study further supports either a strategy of checking 25OHD3 levels and supplementing when needed, or simply supplementing pretty much everyone in the northern climates....

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more